MRG003 (becotatug vedotin) for small cell lung cancer that has come back
Tests MRG003 (becotatug vedotin) in adults whose small cell lung cancer has returned.
Plain-language title generated from the registry record
Registry title: Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC
Key facts
- Where
- Shanghai, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with extensive-stage small cell lung cancer whose cancer came back or got worse after earlier treatment. Everyone receives becotatug vedotin.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Small cell lung cancer confirmed by tissue testing, extensive-stage, with the cancer coming back or growing after prior treatment. At least one lesion that can be measured.
- Earlier treatment
- Must have had earlier treatment for the cancer. Must not have had any anticancer therapy within the set washout period before the first dose.
Main reasons for not taking part
- Interstitial lung disease or other past lung inflammation or fibrosis needing treatment
- HIV infection or AIDS
- Active autoimmune disease or ongoing steroid or immune-suppressing treatment
- Another cancer within the last 3 years, with a few exceptions
- Pregnancy or breastfeeding
Read by machine on 13 November 2026.
Where in China
- Shanghai Pulmonary HospitalShanghai, ChinaContact: Peng Zhang, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shanghai Pulmonary Hospital, Shanghai, China
- Trial code
- NCT07874581
- Record updated
- 15 October 2026
- Original description
This is a single-center, single-arm, exploratory clinical study evaluating the efficacy and safety of MRG003 (Becotatug Vedotin) in patients with relapsed small cell lung cancer. Eligible patients receive becotatug vedotin at a dose of 2.3 mg/kg administered by intravenous infusion once every 21 days until disease progression or unacceptable toxicity. The primary endpoint is overall survival (OS). Secondary endpoints include progression-free survival (PFS), objective response rate (ORR), and safety.Read full original descriptionShow less
Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Patients With Relapsed Small Cell Lung Cancer: A Single-Center, Single-Arm, Exploratory Study
This is a single-center, single-arm, exploratory clinical study evaluating the efficacy and safety of MRG003 (Becotatug Vedotin) in patients with relapsed small cell lung cancer. Eligible patients receive becotatug vedotin at a dose of 2.3 mg/kg administered by intravenous infusion once every 21 days until disease progression or unacceptable toxicity. The primary endpoint is overall survival (OS). Secondary endpoints include progression-free survival (PFS), objective response rate (ORR), and safety.
Inclusion: Signed informed consent form (ICF); Age ≥18 years at the time of signing informed consent; Histologically confirmed small cell lung cancer (SCLC); Extensive-stage SCLC (ES-SCLC) with disease progression or recurrence after prior treatment; At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as assessed by the investigator; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; Adequate organ and bone marrow function; Women of childbearing potential must use highly effective contraception from screening until 3 months after discontinuation of study treatment and must have a negative pregnancy test (serum or urine) within 7 days before enrollment. Male participants must agree to use appropriate contraception from screening until 3 months after discontinuation of study treatment or have undergone surgical sterilization; No anticancer therapy was received within the specified washout period before the first dose of study treatment; Estimated life expectancy ≥12 weeks.
Exclusion: Major surgery (excluding diagnostic biopsy) within 4 weeks before the first dose of study treatment; Current systemic corticosteroid therapy (e.g., prednisone equivalent >10 mg/day) or use of any other immunosuppressive therapy within 14 days before the first dose of study treatment; Interstitial lung disease (ILD), or previous ILD requiring corticosteroid treatment; Receipt of live vaccines within 28 days before the first dose of study treatment; Known hypersensitivity to becotatug vedotin; History of another active malignancy requiring treatment or history of allogeneic organ transplantation; History of drug abuse, chronic alcohol abuse, AIDS, or HIV infection; Active autoimmune disease or history of autoimmune disease with potential risk of recurrence; History of idiopathic pulmonary fibrosis (IPF), drug-induced pneumonitis, organizing pneumonia (including bronchiolitis obliterans organizing pneumonia), or idiopathic pneumonia; Any disease or condition that may contraindicate anticancer therapy, including but not limited to active infection, myocardial infarction within 6 months, symptomatic cardiac disease (including unstable angina, congestive heart failure, or uncontrolled arrhythmia), or ongoing immunosuppressive therapy; Evidence of hereditary bleeding disorders or coagulation abnormalities; Any other medical history, disease, treatment, or laboratory abnormality that may interfere with study results, prevent full participation in the study, or make the participant unsuitable for enrollment as judged by the investigator; History of malignancy within the previous 3 years, except for adequately treated non-melanoma skin cancer or carcinoma in situ with an expected survival of >3 years, such as breast cancer in situ, oral carcinoma in situ, or cervical carcinoma in situ; Pregnancy or breastfeeding; or male or female participants unwilling to use appropriate contraception when pregnancy is possible.